AltStreet
EDGAR Verified
Primary Source · SEC.gov

SV8 Biotech Fund LP

CIK 0002070013Fund Vehicle2026 vintage506(b), 506(c), Rule 504, 4(a)(5)

Raised

Pre-open

Investors

—

Min Invest

$0

AltStreet Analysis

·

Generated from EDGAR primary sources

SV8 Biotech Fund LP is a Delaware-based alternative investment fund filing under an amended Form D on 2026-06-29. The filing does not disclose total capital raised, investor count, or first sale date. The fund claims multiple exemptions simultaneously: 506(b), 506(c), Rule 504, and 4(a)(5).

This alternative investment fund employs an unusual multi-exemption strategy, claiming four separate Regulation D and Securities Act exemptions concurrently (506(b), 506(c), Rule 504, and 4(a)(5)). The lack of disclosed capital raise, investor data, and minimum investment parameters is atypical for alternative funds at the amendment stage, where material terms are generally available.

Data Flags

exemptionFour exemptions claimed simultaneously (506(b), 506(c), Rule 504, 4(a)(5)) — an uncommon filing pattern that may indicate multi-tranche structure or serial offerings under different exemption frameworks
total_amount_soldAmendment filing with no capital raise disclosed and no first sale date — suggests pre-launch or structural amendment rather than capital activity update
industry_groupIndustry group, securities type, state of incorporation, and related persons all left unspecified despite amendment status

EDGAR Filing Data

Form D — Primary Source

View on SEC.gov
CIK Number0002070013
Entity NameSV8 Biotech Fund LP
Exemption506(b), 506(c), Rule 504, 4(a)(5)
First Sale Date—
Filing DateJune 29, 2026
Accession Number0002070013-26-000001
Total Amount Sold—
Total Investors—
Minimum Investment$0 (no stated minimum)
Securities Type—
State of IncorporationNot specified
Amendment CountOriginal filing only

Is this your offering?

Claim this profile to add contact information, team members, LinkedIn profiles, fund history, and additional financial data. EDGAR-sourced data and AltStreet analysis cannot be edited, but corrections can be requested for verifiable inaccuracies.

Claim Profile — FreeGet Verified — $2,400/yr

Data Methodology

Capital raise figures, investor counts, and filing dates are sourced directly from SEC EDGAR Form D primary documents via the SEC EDGAR submissions API and full-text search index. EDGAR entity profiles and deal-level data are reviewed by AltStreet analysts with backgrounds in corporate finance and securities law — cross-referenced against offering circulars, audited financial statements, and primary regulatory filings before publication. Platform-provided information, where present, is clearly labeled and does not affect EDGAR data or AltStreet editorial coverage. Platforms may request factual corrections for demonstrable inaccuracies by contacting [email protected]. This page does not constitute investment advice.